Resumen: Incyte da a conocer los datos a largo plazo de 24 semanas del ensayo de fase III TRuE-AD4 de la crema Opzelura® (ruxolitinib) en adultos con dermatitis atópica moderada

Key Takeaway: Incyte has announced long-term data from the Phase III TRuE-AD4 trial of Opzelura® (ruxolitinib) for adults with moderate atopic dermatitis. The results cover a 24-week period, providing insights into the treatment's efficacy and safety. Further details on the findings were not disclosed in the article.